FIGURE 3.

Chronic treatment with Q134R has little effect on white blood cell counts and enhances survival in adult mice. (a) Table showing mean ± SEM peripheral blood cell counts in 6‐month‐old WT mice measured before and at 4 and 12 weeks during treatment (2× daily, oral gavage) with vehicle (Veh) or Q134R (Q1, 4 mg/kg). Cell types include white blood cells (WBC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), red blood cells (RBC), and platelets. No effects of drug treatment or timepoint were found, except for RBCs, which showed a slight decrease in Q134R mice at 12 weeks relative to baseline. n = 9–10 mice per group; *p < 0.05, within group comparison of baseline vs. 12‐week time point. (b) Kaplan–Meier curves for WT mice gavaged with Veh or Q134R (Q1, 4 mg/kg). Drug treatment was initiated at 52 weeks of age and mice were followed until time of death. Q134R enhanced survival across the lifespan. n = 16 mice per group